Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
83.39
+0.95 (1.15%)
At close: Nov 7, 2025, 4:00 PM EST
84.00
+0.61 (0.73%)
After-hours: Nov 7, 2025, 7:46 PM EST
Edwards Lifesciences Revenue
Edwards Lifesciences had revenue of $1.55B in the quarter ending September 30, 2025, with 14.67% growth. This brings the company's revenue in the last twelve months to $5.88B, up 10.60% year-over-year. In the year 2024, Edwards Lifesciences had annual revenue of $5.44B with 8.57% growth.
Revenue (ttm)
$5.88B
Revenue Growth
+10.60%
P/S Ratio
8.32
Revenue / Employee
$372,392
Employees
15,800
Market Cap
48.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.44B | 429.50M | 8.57% |
| Dec 31, 2023 | 5.01B | 546.00M | 12.23% |
| Dec 31, 2022 | 4.46B | -768.50M | -14.69% |
| Dec 31, 2021 | 5.23B | 846.20M | 19.29% |
| Dec 31, 2020 | 4.39B | 38.30M | 0.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EW News
- 9 days ago - Edwards Lifesciences Corporation (EW) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Edwards Lifesciences beats quarterly estimates on strength in heart devices - Reuters
- 9 days ago - Edwards Lifesciences CFO Scott Ullem to step down by mid-2026 - Reuters
- 9 days ago - Edwards Lifesciences Announces CFO Transition Plan - Business Wire
- 9 days ago - Edwards Lifesciences Reports Third Quarter Results - Business Wire
- 11 days ago - Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 12 days ago - EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW - GlobeNewsWire
- 12 days ago - Successful Patient Outcomes Demonstrated With Edwards' SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025 - Business Wire